Efficacy and Safety of Seltorexant as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Phase 2b, Randomized, Placebo-Controlled, Parallel-Group, Adaptive Dose-Finding Study

被引：0
|
作者：
Savitz, Adam [1 ]
Wajs, Ewa [1 ]
Zhang, Yun [1 ]
Xu, Haiyan [1 ]
Etropolski, Mila [1 ]
Saoud, Jay [1 ]
Luthringer, Remy [1 ]
Drevets, Wayne [1 ]
机构：
[1] Janssen Res & Dev LLC, Titusville, NJ USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2019年 / 44卷 / SUPPL 1期
关键词：
Adjunctive Therapy; Major Depressive Disorder (MDD); Orexin; Seltorexant;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
M86
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [41] Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial
    Zandifar, Atefeh
    Panahi, Maryam
    Badrfam, Rahim
    Qorbani, Mostafa
    BMC PSYCHIATRY, 2024, 24 (01)
  • [42] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Lynde, Charles
    Alam, Maryam Shayesteh
    Sadick, Neil
    Rohan, Craig A.
    Werschler, William Philip
    Hebert, Adelaide A.
    Laquer, Vivian T.
    Sauder, Maxwell
    Del Rosso, James Q.
    Rodgers, Timothy
    Tan, Ricardo
    Schleicher, Stephen
    Murrell, Dedee F.
    Fernandez-Penas, Pablo
    Reich, Adam
    Gkalpakiotis, Spyridon
    Ruiz, Juan Ruano
    Wollenberg, Andreas
    Szepietowski, Jacek C.
    Sticherling, Michael
    Weyergraf, Ansgar J.
    Hadzavdic, Suzana Ljubojevic
    Baran, Wojciech
    Vilchez, Trinidad Montero
    Eniko, Telegdy
    Sebastian, Michael
    Chaudhry, Sohail
    Lee, Zachary
    Yu, Danni
    Liu, Yi
    Waltz, Wang
    Gilbert, Jenny
    Elko-Simms, Lucinda M.
    Fanton, Christie
    Jue, Charleen
    Tagliaferri, Mary
    Zalevsky, Jonathan
    Rosmarin, David
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 105 - 107
  • [43] A Randomized, Double-Blind, Placebo-Controlled Study of Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
    Hobart, Mary
    Skuban, Aleksandar
    Zhang, Peter
    Yang, Ye
    Augustine, Carol
    Brewer, Claudette
    Hefting, Nanco
    Sanchez, Raymond
    McQuade, Robert
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S533 - S533
  • [44] Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Avrameas, Alexandre
    Luo, Wen-Lin
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2025,
  • [45] Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    Teerlink, John R.
    Metra, Marco
    Felker, G. Michael
    Ponikowski, Piotr
    Voors, Adriaan A.
    Weatherley, Beth Davison
    Marmor, Alon
    Katz, Amos
    Grzybowski, Jacek
    Unemori, Elaine
    Teichman, Sam L.
    Cotter, Gad
    LANCET, 2009, 373 (9673): : 1429 - 1439
  • [46] Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
    Peter V. Dicpinigaitis
    Alyn H. Morice
    Jaclyn A. Smith
    Mandel R. Sher
    Michael Vaezi
    Laurent Guilleminault
    Akio Niimi
    Kerstin Gude
    Ulrike Krahn
    Riitta Saarinen
    Philippe Vieira Pires
    Melanie Wosnitza
    Lorcan McGarvey
    Lung, 2023, 201 : 255 - 266
  • [47] Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
    Dicpinigaitis, Peter H.
    Morice, Alyn A.
    Smith, Jaclyn R.
    Sher, Mandel
    Vaezi, Michael
    Guilleminault, Laurent
    Niimi, Akio
    Gude, Kerstin
    Krahn, Ulrike
    Saarinen, Riitta
    Pires, Philippe Vieira
    Wosnitza, Melanie
    McGarvey, Lorcan
    PAGANINI Investigators
    LUNG, 2023, 201 (03) : 255 - 266
  • [48] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
    Muir, A.
    Goodman, Z.
    Levy, C.
    Janssen, H.
    Montano-Loza, A.
    Bowlus, C.
    Ding, D.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Manns, M.
    Chapman, R.
    Afdhal, N.
    Eksteen, B.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
  • [49] Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
    Inoue, Takeshi
    Sasai, Kiyofumi
    Kitagawa, Tadayuki
    Nishimura, Akira
    Inada, Isao
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (02) : 140 - 148
  • [50] A randomized, blinded, placebo-controlled, phase II, dose-finding study of ARANESP™ in patients with lymphoproliferative malignancies.
    Hedenus, M
    Hansen, S
    Dewey, C
    Watson, D
    Colowick, A
    Osterborg, A
    BLOOD, 2000, 96 (11) : 155B - 155B
12345